MedTrace Logo

A Study of Experimental Medication BMS-986036 Given to Healthy Participants

NCT03445208 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-03-19

No results posted yet for this study

Summary

This is a study of experimental medication BMS-986036 given to healthy participants.

Conditions

Interventions

DRUG

BMS-986036

Crossover administration to abdomen then upper arm

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-14
Primary Completion
2018-05-02
Completion
2018-05-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03445208 on ClinicalTrials.gov